PROTARA THERAPEUTICS
Protara Therapeutics develops transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy created for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. The Protara team prioritizes creativity, diverse perspectives, and tenacity to expedite their goal of bringing life-changing therapies to people with limited treatment options.
PROTARA THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.protaratx.com
Total Employee:
11+
Status:
Active
Contact:
646-844-0337
Total Funding:
4.15 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Microsoft Azure DNS GoDaddy DNS Digital Ocean Akamai Hosted IHS Markit
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Board_member
2018-01-01
Board_member
2021-01-01
Current Employees Featured
Jacqueline Zummo Co-founder, Senior Vice President and Chief Scientific Operations Officer @ Protara Therapeutics
Co-founder, Senior Vice President and Chief Scientific Operations Officer
2020-01-01
Blaine Davis CFO @ Protara Therapeutics
CFO
2022-01-01
Jathin Bandari Chief Medical Officer @ Protara Therapeutics
Chief Medical Officer
2022-01-01
Jesse Shefferman Co-founder, Director and Chief Executive Officer @ Protara Therapeutics
Co-founder, Director and Chief Executive Officer
2017-01-01
Founder
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-21 | Protara Therapeutics Announces Departure of Chief Financial Officer |
| 2022-01-10 | Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer |
Official Site Inspections
http://www.protaratx.com
- Host name: protara.wpmudev.host
- IP address: 104.156.225.247
- Location: Matawan United States
- Latitude: 40.4652
- Longitude: -74.2307
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07747
More informations about "Protara Therapeutics"
Investor Overview – Protara Therapeutics, Inc.
Nov 15, 2024 info@protaratx.com. Investor contact: Justine O’Malley Phone: +1 646-817-2836 Justine.OMalley@protaratx.com. Phone: +1 646-844-0337 info@protaratx.com. Investor …See details»
BOARD OF DIRECTORS | Protara Therapeutics
Dr. Michael Solomon has served on Protara’s board of directors since May 2018. He currently serves as Chief Executive Officer and on the board of directors of Ribometrix, Inc., a company focused on targeting RNA with small molecules, …See details»
Protara Therapeutics - Crunchbase Company Profile & Funding
Organization. Protara Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email info@protaratx.com; …See details»
Committee Composition - Protara Therapeutics, Inc.
Info@protaratx.com. Investor contact: Justine O’Malley Phone: +1 646-817-2836 Justine.OMalley@protaratx.com. Phone: +1 646-844-0337 info@protaratx.com. Investor …See details»
Protara Therapeutics - LinkedIn
Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in ...See details»
Protara Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Company Contact:Justine O'MalleyProtara TherapeuticsJustine.OMalley@protaratx.com646-817-2836Source: Protara Therapeutics Clinical Result Phase 2 Orphan Drug 100 Deals associated …See details»
Protara Therapeutics - Overview, News & Similar companies
May 21, 2024 Protara Therapeutics contact info: Phone number: (646) 844-0337 Website: www.protaratx.com What does Protara Therapeutics do? Protara is focused on identifying and …See details»
ABOUT US | Protara Therapeutics
Cookie Duration Description; _ga: 2 years: The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report.See details»
Proteon Therapeutics and ArTara Therapeutics Agree to Combine
Sep 23, 2019 Management and Organization. The combined company will be led by Jesse Shefferman, ArTara Chief Executive Officer, and will be headquartered in New York, NY. The …See details»
PIPELINE | Protara Therapeutics
PIPELINE We have established a portfolio of de-risked assets addressing rare diseases and oncology. Indication Pre-Clinical Phase 1 Phase 2 Phase 3 O ...See details»
Protara Therapeutics Announces Appointment of Cynthia Smith to …
For more information, visit www.protaratx.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward …See details»
Protara Therapeutics Announces First Quarter 2024 Financial …
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and …See details»
Protara Therapeutics Announces Fourth Quarter and Full Year …
Mar 13, 2024 Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise …See details»
Presentations – Protara Therapeutics, Inc.
Dec 2, 2022 Please reach out to Justine O’Malley (Justine.OMalley@protaratx.com) to learn more. Print. Print; Email Alerts. Email Alerts; RSS Feeds. RSS Feeds; Email Page. Email …See details»
PRIVACY POLICY | Protara Therapeutics
We encourage parents with concerns to contact us at privacy@Protaratx.com. Residents of the European Economic Area, Switzerland and the United Kingdom If you reside in the European …See details»
INVESTORS | Protara Therapeutics
INVESTORS Investor Overview Press releases Events and presentations Analyst coverage Sec filings Stock information Corporate governance Information Request ...See details»
Press Releases - Protara Therapeutics, Inc.
Nov 15, 2024 info@protaratx.com. Investor contact: Justine O’Malley Phone: +1 646-817-2836 Justine.OMalley@protaratx.com. Phone: +1 646-844-0337 info@protaratx.com. Investor …See details»
Protara Therapeutics Announces Fourth Quarter and Full Year …
Following a successful meeting with the FDA in 2018 regarding the registration package for IV Choline Chloride, the Company is currently undertaking a prevalence study in partnership with …See details»
CLINICAL TRIALS | Protara Therapeutics
Open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC who are BCG …See details»